🇺🇸 FDA
Pipeline program

Farxiga® (dapagliflozin) + Onglyza® (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes

ANDA219975 + ANDA220011

Phase 3 small_molecule active

Quick answer

Farxiga® (dapagliflozin) + Onglyza® (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes for Type 2 Diabetes is a Phase 3 program (small_molecule) at Design Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Design Therapeutics
Indication
Type 2 Diabetes
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials